Gal-3 has been closely associated with a poor prognosis of primary HCC, by promoting tumor cell growth, migration and invasion, stimulating angiogenesis and enhancing the tumorigenesis and metastasis of HCC cells [24,42,43]. After persistent HBV infection, Gal-3 was demonstrated to play a key role in adverse disease progression and to be a potential therapeutic target [44]. In this study, LGALS3 expression was negatively correlated with the overall survival of HCC patients (Figure 8C), which was consistent with the levels of ITGB1 and IL-10 (Figure S3). This evidence concerns the gene LGALS3 and hepatocellular carcinoma.